JP4223560B2 - スルホン酸又はスルホニルアミノn−(ヘテロアラルキル)アザヘテロシクリルアミド化合物 - Google Patents

スルホン酸又はスルホニルアミノn−(ヘテロアラルキル)アザヘテロシクリルアミド化合物 Download PDF

Info

Publication number
JP4223560B2
JP4223560B2 JP52684498A JP52684498A JP4223560B2 JP 4223560 B2 JP4223560 B2 JP 4223560B2 JP 52684498 A JP52684498 A JP 52684498A JP 52684498 A JP52684498 A JP 52684498A JP 4223560 B2 JP4223560 B2 JP 4223560B2
Authority
JP
Japan
Prior art keywords
ylmethyl
oxopyrrolidin
sulfonic acid
optionally substituted
methoxynaphthalene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP52684498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001506630A5 (cg-RX-API-DMAC7.html
JP2001506630A (ja
Inventor
スレデスキー ヨン ミー チョイ
ヘンリー ダブリュー ポールス
ジェフリー エヌ バートン
ウィリアム アール エウイング
ダニエル エム グリーン
マイケル アール ベッカー
Original Assignee
アヴェンティス ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アヴェンティス ファーマシューティカルズ インコーポレイテッド filed Critical アヴェンティス ファーマシューティカルズ インコーポレイテッド
Publication of JP2001506630A publication Critical patent/JP2001506630A/ja
Publication of JP2001506630A5 publication Critical patent/JP2001506630A5/ja
Application granted granted Critical
Publication of JP4223560B2 publication Critical patent/JP4223560B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP52684498A 1996-12-13 1997-12-03 スルホン酸又はスルホニルアミノn−(ヘテロアラルキル)アザヘテロシクリルアミド化合物 Expired - Fee Related JP4223560B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3315996P 1996-12-13 1996-12-13
US60/033,159 1996-12-13
PCT/US1997/022406 WO1998025611A1 (en) 1996-12-13 1997-12-03 Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds

Publications (3)

Publication Number Publication Date
JP2001506630A JP2001506630A (ja) 2001-05-22
JP2001506630A5 JP2001506630A5 (cg-RX-API-DMAC7.html) 2005-08-11
JP4223560B2 true JP4223560B2 (ja) 2009-02-12

Family

ID=21868858

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52684498A Expired - Fee Related JP4223560B2 (ja) 1996-12-13 1997-12-03 スルホン酸又はスルホニルアミノn−(ヘテロアラルキル)アザヘテロシクリルアミド化合物

Country Status (23)

Country Link
EP (1) EP0944386B1 (cg-RX-API-DMAC7.html)
JP (1) JP4223560B2 (cg-RX-API-DMAC7.html)
KR (1) KR20000057528A (cg-RX-API-DMAC7.html)
CN (1) CN1244798A (cg-RX-API-DMAC7.html)
AP (1) AP1032A (cg-RX-API-DMAC7.html)
AT (1) ATE224192T1 (cg-RX-API-DMAC7.html)
AU (1) AU726637B2 (cg-RX-API-DMAC7.html)
BG (1) BG103558A (cg-RX-API-DMAC7.html)
BR (1) BR9713921A (cg-RX-API-DMAC7.html)
CA (1) CA2274686C (cg-RX-API-DMAC7.html)
DE (1) DE69715658T2 (cg-RX-API-DMAC7.html)
DK (1) DK0944386T3 (cg-RX-API-DMAC7.html)
EA (1) EA002817B1 (cg-RX-API-DMAC7.html)
ES (1) ES2184145T3 (cg-RX-API-DMAC7.html)
HU (1) HUP9904188A3 (cg-RX-API-DMAC7.html)
IL (1) IL130152A0 (cg-RX-API-DMAC7.html)
NO (1) NO312416B1 (cg-RX-API-DMAC7.html)
OA (1) OA11062A (cg-RX-API-DMAC7.html)
PL (1) PL333921A1 (cg-RX-API-DMAC7.html)
PT (1) PT944386E (cg-RX-API-DMAC7.html)
SK (1) SK71299A3 (cg-RX-API-DMAC7.html)
WO (1) WO1998025611A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA9711207B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002517393A (ja) * 1998-06-03 2002-06-18 アベンティス・ファーマスーティカルズ・プロダクツ・インコーポレイテツド スルホン酸またはスルホニルアミノn−(ヘテロアラルキル)−アザヘテロシクリルアミド化合物

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281227B1 (en) * 1996-12-13 2001-08-28 Aventis Pharma Deutschland Gmbh Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
IL123986A (en) * 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
AR016817A1 (es) 1997-08-14 2001-08-01 Smithkline Beecham Plc Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
WO1999011658A1 (en) 1997-08-29 1999-03-11 Proteus Molecular Design Ltd. Meta-benzamidine derivatives as serin protease inhibitors
WO1999016747A1 (en) 1997-09-30 1999-04-08 Daiichi Pharmaceutical Co., Ltd. Sulfonyl derivatives
AU753675B2 (en) 1998-03-19 2002-10-24 Ajinomoto Co., Inc. Aminoisoquinoline derivatives
EP1104754A1 (en) * 1998-08-11 2001-06-06 Daiichi Pharmaceutical Co., Ltd. Novel sulfonyl derivatives
EP1283199A4 (en) * 2000-05-16 2003-12-17 Takeda Chemical Industries Ltd MELANINE CONCENTRATING HORMONE ANTAGONISTS
GB0114004D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114005D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0127568D0 (en) 2001-11-16 2002-01-09 Glaxo Group Ltd Chemical compounds
WO2003106445A1 (en) * 2002-06-12 2003-12-24 Qsi Pharma A/S Compounds and methods for controlling bacterial virulence
CN100513398C (zh) 2002-12-03 2009-07-15 Axys药物公司 作为因子viia抑制剂的2-(2-羟基联苯-3-基)-1h-苯并咪唑-5-甲脒衍生物
EP1784410A4 (en) * 2004-08-09 2009-07-15 Glaxo Group Ltd ANTIBACTERIAL AGENTS
FR2890072A1 (fr) 2005-09-01 2007-03-02 Fournier S A Sa Lab Nouveaux composesde pyrrolopyridine
JP5147401B2 (ja) * 2005-09-06 2013-02-20 塩野義製薬株式会社 Pgd2受容体アンタゴニスト活性を有するインドールカルボン酸誘導体
FR2955110A1 (fr) 2010-01-08 2011-07-15 Fournier Lab Sa Nouveaux derives de type pyrrolopyridine benzoique
EP2606893A1 (en) * 2011-12-21 2013-06-26 Sanofi Sulphonylaminopyrrolidinone derivatives, their preparation and their therapeutic application
CN104098497B (zh) * 2014-06-17 2016-04-13 王庚禹 一种新的酰胺类化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4121947A1 (de) * 1991-07-03 1993-01-07 Basf Ag 2-(3-(4-amidino-phenyl))-propionsaeurederivate, ihre herstellung und verwendung
JPH10503176A (ja) * 1994-06-17 1998-03-24 コーバス インターナショナル, インコーポレイテッド 酵素インヒビターとしての3−アミノ−2−オキソ−1−ピペリジン酢酸誘導体
US5612353A (en) * 1995-06-07 1997-03-18 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002517393A (ja) * 1998-06-03 2002-06-18 アベンティス・ファーマスーティカルズ・プロダクツ・インコーポレイテツド スルホン酸またはスルホニルアミノn−(ヘテロアラルキル)−アザヘテロシクリルアミド化合物

Also Published As

Publication number Publication date
ZA9711207B (en) 1998-07-20
ATE224192T1 (de) 2002-10-15
AU726637B2 (en) 2000-11-16
WO1998025611A1 (en) 1998-06-18
AP1032A (en) 2001-12-24
IL130152A0 (en) 2000-06-01
BR9713921A (pt) 2000-03-21
CA2274686C (en) 2009-02-03
EA199900542A1 (ru) 2000-02-28
EP0944386A1 (en) 1999-09-29
KR20000057528A (ko) 2000-09-25
DK0944386T3 (da) 2003-01-27
NO992853D0 (no) 1999-06-11
OA11062A (en) 2002-03-11
PT944386E (pt) 2003-01-31
HUP9904188A3 (en) 2003-02-28
PL333921A1 (en) 2000-01-31
CN1244798A (zh) 2000-02-16
HUP9904188A1 (hu) 2000-06-28
NO992853L (no) 1999-08-10
DE69715658D1 (de) 2002-10-24
EA002817B1 (ru) 2002-10-31
ES2184145T3 (es) 2003-04-01
CA2274686A1 (en) 1998-06-18
DE69715658T2 (de) 2003-05-22
EP0944386B1 (en) 2002-09-18
JP2001506630A (ja) 2001-05-22
AU5518298A (en) 1998-07-03
NO312416B1 (no) 2002-05-06
BG103558A (en) 2000-04-28
EP0944386A4 (en) 2001-04-11
SK71299A3 (en) 2000-12-11
AP9901552A0 (en) 1999-06-30

Similar Documents

Publication Publication Date Title
US6281227B1 (en) Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
EP0944386B1 (en) Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
EP1051176B1 (en) SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS
US6602864B1 (en) Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds
KR100291711B1 (ko) 3치환된(술핀산,술폰산,술포닐아미노또는술피닐아미노)n-(아미노이미노메틸)페닐알킬)-아자헤테로시클릴아미드화합물및이를포함하는약제학적조성물
JP4107687B2 (ja) 置換n―[(アミノイミノメチル又はアミノメチル)フェニル]プロピルアミド
JP4053597B2 (ja) 置換n―[(アミノイミノメチル又はアミノメチル)フェニル]プロピルアミド
EA001739B1 (ru) Замещенные n-[(аминоиминометил)фенилалкил]азагетероцикламиды сульфоновых кислот
JP2003529531A (ja) 置換オキソアザへテロシクリルXa因子阻害剤
JPH08507072A (ja) フィブリノーゲンレセプターアンタゴニスト
JPH09501435A (ja) フィブリノーゲン受容体拮抗剤
HRP20010903A2 (en) Pyrazinone thrombin inhibitors
MXPA99005483A (en) Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
CZ211599A3 (cs) Sulfonové nebo sulfonylaminové N- (heteroaralkyl)-azaheterocyklylamidové sloučeniny
CZ20004497A3 (en) Sulfonyl- or sulfonylamino-N-(heteroaralkyl)azaheterocyclylamide derivatives and pharmaceutical preparation containing thereof
MXPA00011884A (en) Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
HK1030741A (en) Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080829

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20081021

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20081120

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111128

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111128

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121128

Year of fee payment: 4

LAPS Cancellation because of no payment of annual fees